title: Investigation of Appropriate Inhalation Technique for Mometasone Furoate Dry Powder Inhaler.
abstract: The aim of this study was to establish an appropriate inhalation method with a mometasone furoate dry powder inhaler (MF-DPI). Utilizing a tone-based inhalation training device, we investigated the maximum peak inspiratory flow rate time (TmaxPIFR) and peak inspiratory flow rate (PIFR) to determine whether either had an influence on lung deposition with use of an MF-DPI. A low tone indicated a PIFR of 28 L/min and a high tone that of 40 L/min, while 60 L/min was considered to be the standard. We established an inhalation profile in consideration of a human inhalation pattern, in which TmaxPIFR was set at 0.5 s (TmaxPIFR 0.5 s) and 2.5 s (TmaxPIFR 2.5 s). The reference cut-off value derived with a cascade impactor test was used for evaluation of the rate of delivered dose in the lung, which was the amount of drug from stage 3 to 7 at all PIFRs. We then investigated the relationship of the fine particle fraction (FPF) with the claimed dose at TmaxPIFR of 0.5 s and PIFR. There were no differences among the TmaxPIFR values for the doses emitted from the device or for the rate of delivered doses in stages 3-7. However, FPF for the claimed dose at 40 L/min was significantly lower than that at 60 L/min, which was dependent on PIFR. Our results showed that PIFR but not TmaxPIFR has an effect on lung deposition after inhalation with an MF-DPI.
authors.affiliation: Department of Clinical Evaluation of Drug Efficacy, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences.
authors.forename: Haruko
authors.initials: H
authors.lastname: Yokoyama
authors.forename: Kanako
authors.initials: K
authors.lastname: Ito
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Mihashi
authors.forename: Yasuyuki
authors.initials: Y
authors.lastname: Shiraishi
authors.forename: Risa
authors.initials: R
authors.lastname: Takayanagi
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Yamada
mesh_terms: D000280:Administration, Inhalation; D018926:Anti-Allergic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D058995:Dry Powder Inhalers; D006801:Humans; D008168:Lung / Q000378:metabolism* / Q000502:physiology; D000068656:Mometasone Furoate / Q000008:administration & dosage* / Q000493:pharmacokinetics; D012123:Pulmonary Ventilation
chemical_list: D018926:Anti-Allergic Agents; D000893:Anti-Inflammatory Agents; D000068656:Mometasone Furoate